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Discussion
Dr Charles D. Fraser (Houston, Tex). I would really like to
congratulate Dr Gaynor and colleagues for yet another important
contribution to the search for understanding of the complexities
of abnormal neurodevelopmental outcomes in children requiring
cardiac surgery. This study presented on behalf of the Pediatric
Heart Network Infant Single Ventricle Trial and the Single
Ventricle Reconstruction Trial investigators sought to validate
work that Dr Gaynor has previously conducted in a group of
newborn infants with varying cardiac diagnoses in which the
Apo-lipoprotein E E2 allele was associated with poorer
neurodevelopmental outcomes as determined in 224 infants using
the Bayley II Scale of Infant Development (BSID) evaluated by
the Psychomotor Developmental Index (PDI) and the Mental
Developmental Index (MDI).
The present study focuses on single-ventricle patients,
predominantly children with hypoplastic left heart syndrome
who survived to undergo the BSID evaluation at 14 months of
life and whose APOE genotype had been assessed; from the initial
combined cohort of 713 individuals; 298 patients were eligible for
this study. And as Dr Gaynor has so elegantly presented, important
findings include a median PDI of 76.9, normal being 100, and a
median MDI of 90.6, also normal being 100.
For the entire cohort, the APOE E2 allele was associated with a
statistically significant lower PDI score and a lower MDI score
approaching significance. Then after removing clearly syndromic
patients from the analysis, both PDI and MDI scores were
significantly lower in children with the E2 allele. Of note, and
part of my questioning below, the E2 allele was calculated to
explain roughly 1% of the overall PDI and MDI variance, but
the site of the surgery was most strongly associated with the
observed variation accounting for between 10% and 15% of the
variation.
So my questions are:
(1) Given these results, can genotyping for the E2 allele now be
added to our armamentarium in counseling families about neuro-
developmental risk in their newborn infants facing cardiac sur-
gery? And can this be extended into fetal life or should it be?
Dr Gaynor. Again, I think it is hard to know until we can actu-
ally do something about it. When we actually set up our original
study, the Institutional Review Board told us we could not tell
the families what gene we were testing or what the result was,
because they were concerned that the epsilon 4 allele is the 1 asso-
ciated with the risk of Alzheimer disease and they were concerned
that we would be giving them news that would make them worry
that we could do nothing about.
I think for clinical trials, yes, it is going to be something that will
help us understand the variation. If we develop a therapeutic strat-gery c December 2014
Gaynor et al Congenital Heart Disease
C
H
Degy that can be based on the genotype, then it should definitely be
incorporated into it. I do not think I would recommend it for
routine care until we have a therapy based on it.
Dr Fraser. I do not want to dominate the discussion, but I have
to have a corollary to that question though. So you are going to
publish this and there are going to be parents who are going to
find out this information and they are going to ask you, ‘‘Should
my child have a genotype for this?’’ The answer would be ‘‘No’’?
Dr Gaynor. I would tell them right now there is nothing we can
do at the current time to change our therapy based on this
genotype.
Dr Fraser. Question 2: you note the increasing evidence that
APOE protein is important for neuronal repair and patients with
abnormal APOE genotype are more susceptible to oxidative
stress-related neuronal injury; is it not logical to conclude that
perioperative strategies that mitigate the potential for neuronal
injury should have benefit as modifiable risk factors for neurode-
velopmental outcome because at present we are unable to modify
the genotype?
Dr Gaynor. If we could find a strategy that might mitigate the
risk, that would make sense. Currently, the best evidence we have
is based on neural imaging techniques and early neurodevelop-
mental outcomes. Of all the strategies, continuous bypass, ante-
grade cerebral perfusion, deep hypothermic circulatory arrest, all
are associated with somewhere between a 30% and 40% incidence
of new injury based on early magnetic resonance imaging. That is
from our institution, your institution, multiple other institutions.
In a recent large study from New Zealand, they looked at the
risk of new injury and neurodevelopmental outcomes, and the
degree of brain immaturity at the time of surgery was a more
important predictor than the operative management strategies. In
the SVR trial where patients were managed with both deep hypo-
thermic circulatory arrest and antegrade cerebral perfusion, we
could not identify a difference.
If we could identify an operative management strategy that we
could show, then yes, it might make a difference. When we looked
at different groups in our own cohort, we could not identify any
difference in the effect whether or not they had circulatory arrest
or continuous bypass.
Dr Fraser.Well, that is a good segue into my last question, and
particularly provocative given the data that Dr Karamlou presented
earlier. I find it fascinating and to my view the most important
point of your study, frankly, that the strongest association is with
the site of surgery. As per the above, given your previous work
focusing on nonmodifiable risk factors, are you ready to update
your viewpoint on the complex interplay of modifiable and
nonmodifiable causes of injury?
To my reading of this study, although the E2 allele is associated
with some significant level of increased susceptibility, the location
of the child’s surgery has a much stronger influence. My interpre-
tation is that certain centers through the complex interplay of
modifiable perioperative factors (surgery, perioperative care,
cardiopulmonary bypass, and others unknown) are able to achieve
better results in terms of brain protection and we do not fully
understand why.
Dr Gaynor. I would agree. In the SVR paper we struggled with
this. There are several potential things. We do not know if there
are unmeasured differences in the patient populations betweenThe Journal of Thoracic and Carthe centers. To the best we could ascertain, the groups were
similar.
There are clearly differences in operative strategies between the
centers, but what we could measure in terms of bypass manage-
ment, blood gas management, other things like that, none of those
came out.
One of the other things that we did find and we were concerned
about is that there may be some ascertainment by us between cen-
ters. There were some centers where it looked like there was a drift
of scores over time, that the scores either got higher or lower over
time. One of the flaws of the SVR strategy was that we did not have
a retest of the evaluators for the Bayley scales. So there are a
variety of reasons. There may be unmeasured factors. Everything
that we looked at between the centers in terms of patient character-
istics, operative management strategies, we could not identify a
difference. We even did a subgroup analysis looking at Michigan,
Wisconsin, CHOP, and Boston, which have very different strate-
gies, and could not identify any difference in outcomes between
those centers. So we tried to look at that to see if we could identify
either a patient factor or a management strategy that would explain
that, and we are still not sure and there is this lingering concern that
some of it may be due to ascertainment bias.
Dr Fraser. Well, I just have to push on that a little bit. I could
get it if it were a few-fold difference, but it is a 15-fold difference.
Dr Gaynor. I agree. The measured factors that we looked at,
and there may be other factors that we did not, but in the subgroup
analysis of the 4 largest centers contributing, we could not identify
any real difference in outcomes. And where we could look to make
sure the populations were the same and any impact of management
strategies, we could not identify that. That leaves open, there is a
hypothesis, there may be some differences; however, when you
look again from your center, our center, neuroimaging, very
different strategies, and yet we have very similar outcomes. I think
it is an important question, but I do not think we have answered
that yet.
Dr Hillel Laks (Los Angeles, Calif). It was a great paper. Is
there any evidence for this APOE E2 allele, or in patients without
that, that the age at which you are exposed to bypass or circula-
tory arrest makes a difference? In this particular analysis did the
time of surgery with regard to the maturity of the brain make a
difference?
Dr Gaynor. We included age at surgery as 1 of the covariates
and it did not come out.
Dr Laks. And do you have data in terms of the maturity of the
brain; when is the inflection point at which it might be safer to use
these techniques and bypass?
Dr Gaynor. Well, it is hard to know. Based on early postnatal
imaging before surgery, there is about a 4- to 5-week immaturity
of the brain. If you think, we have a baby who is 37 or 38 weeks,
their brain is probably something more along 32 to 33 weeks.
There probably is a population of vulnerable white matter precur-
sors at that point. And we know brain maturation is delayed in
these kids. It suggests you would have to wait 5 to 6 weeks to allow
the brain to come to a normal maturity.
Now, that is problematic in itself. Youmay have to keep the child
in the ICU on prostaglandins. We have some data that was just pre-
sented at the American Heart Association that suggests delaying
stage 1 past about 5 days of life increases the risk of white matterdiovascular Surgery c Volume 148, Number 6 2567
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Dinjury. So I think it is a complex interplay. If they did not require
neonatal surgery or did not have ductal-dependent pulmonary or
systemic blood flow, it might be possible to delay until they are
out of the neonatal period and the brain ismatured.Butmany of these
kids are ductal dependent for either systemic or pulmonary blood
flow.
Dr Laks. But you could argue that an off-pump procedure,
which would get a similar result, would be better if you could delay
the open procedure for at least 5 weeks.
Dr Gaynor. It might be. But again, if you do a shunt off pump,
you may introduce a steal. If you do the hybrid procedure for stage
1, there is concern that then cerebral blood flow is retrograde, up aEDITORIAL CO
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factors, and I do not think the study has been done that would allow
us to answer that question.
Dr Jennifer Hirsch-Romano (Ann Arbor, Mich). I just have 1
other question for you. This gets back to what Chuck Fraser
brought up about the variation across sites. If you looked at the
mortality across those sites, was that associated with worse
neurodevelopmental outcomes at long-term follow-up?
Dr Gaynor. We tried to look at that thinking there might be a
survivor bias, that some sites could get sicker kids through and
they would have worse outcomes, and we could not identify
anything like that.MMENTARYValidation accepted, but look at what else was revealedErle H. Austin III, MDCardiac surgery for neonates and infants has evolved sub-
stantially in the past several decades with significant
improvement in survival for all forms of congenital heart
disease. Survival, of course, is only the first objective. Par-
ents want their child to survive, but they also want their
child to thrive after recovering from heart surgery. Those
of us who care for these patients are paying an increasing
amount of attention to neurodevelopmental outcomes.
One of several areas directed at improving neurodevelop-
mental outcomes is the identification of genetic markers
that correlate with neurologic outcome. In 2003, Gaynor
and colleagues1 demonstrated a significant detrimental
effect of the apolipoprotein E (APOE) ε2 allele on the neu-
rodevelopmental outcome of patients aged 6 months or less
who had undergone cardiac surgery. In this single-center
prospective study, neurodevelopmental evaluation was per-
formed using the Bayley Scales of Infant Development
assessed at 12 months of age. The presence of the ε2 allele
correlated with a 7-point decrease in the Psychomotor
Developmental Index (PDI) compared with patients withoutthat allele. As the apolipoprotein E protein is considered an
important factor in repairing injured neural tissue, the pres-
ence of the ε2 allele in these patients is believed to adversely
affect the ability of the protein to perform such repair after
neonatal and infant heart surgery.
As the authors of the accompanying report2 indicate,
reports of genotype-phenotype associations are rarely vali-
dated. The initial report was the product of much work and
many resources at a center with a substantial volume of
patients. Repeating that process for the sake of validation
was unlikely. Fortunately, it was recognized that the Pediat-
ric Heart Network had been independently studying similar
patients in 2 multicenter trials (the Infant Single Ventricle
[ISV] and the Single Ventricle Reconstruction [SVR] tri-
als). Fortunately, APOE testing had been performed on
the SVR patients and DNA had been extracted from blood
samples of the ISV patients. Furthermore, in both trials,
neurodevelopmental testing (Bayley Scales of Infant
Development-II [BSID-II]) had been performed on most
patients. Thus, the opportunity to validate or refute the find-
ings of the initial report presented itself.
After appropriate selection of patients, the authors of the
current report identified 298 patients with complete APOE
and neurodevelopmental data. The presence of the ε2 allele
imparted a 6-point decrease in PDI score, almost the same
as the 7-point decrement in PDI determined in the primary
report. A decrement in the Mental Developmental Index
(MDI), the other portion of BSID-II, was also seen at a level
just short of significance, but again, similar to what was
found in the initial study. I think it is fair to say this
genotype-phenotype association has been validated. The
authors are to be congratulated for identifying thisgery c December 2014
